-
-
-
-
-
-
-
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
-
-
-
-
-
-
-
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
-
-
-
-
-
-
-
Rafael Holdings (RFL) to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities
-
-
-
-
-
-
-
Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Pat
-
-
-
-
-
-
-
Rafael Holdings Realigns Leadership Team to Support Earlier Stage Pipeline Focus
-
-
-
-
-
-
-
Rafael (RFL) AVENGER 500 Phase 3 clinical trial evaluating CPI-613 in combination with modified FOLFIRINOX (mFFX) as a first-line therapy in patients misses primary endpoint
-
-
-
-
-
-
-
Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08
-
1,167,606 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

